We would like to inform you that the following functions, which were temporarily suspended to address vulnerabilities external systems, have now resumed service following the completion of necessary security measures and safety verifications:

• Freel trial of the analyzer series
• Patient population

Following thorough investigations, including log analyses conducted during the suspension period, we have confirmed no damage, unauthorized access, or data leaks resulting from this vulnerability.

We sincerely apologize for the inconvenience and concern this disruption may have caused.

We remain committed to further strengthening our security measures to ensure that you can continue to use our services safely and securely.